socrates469bc

really is ironic after only 1.5mths after this roadmap. wahahahahhahaha

song bo, smelly peasants??????

ur Towkay will tell u since u save on travelling and grooming expenses with wfh, u shld have more disposable income liao. maybe shld cancel ur other claimable expenses such as handphone bills and petrol as well. wahahahahahhaha

kin kumgong. i alrdy said in 2018 that supply chain re-alignment and production reshoring will hasten under the tariffs. but still have kgks want to argue with me. nb, limpeh me got economics degree and work in international trade, so mai talk cock with me. best part is the Emperor is kumgong enough to engage in the trade war. wahahahahahhahah

maybe @meng.huat kor kor will apply and bring his atbgf there every weekend in his sakti honda vezel.

cag lai cag qu. so who is the real cag????? why dont u 2 kgks open a room at hotel 81 bugis and discuss what constitute a cag????? the 2 of u will be very happy together discussing this topic de.

.......... if got read, how come director of moh bo prepare worst-case scenario for the Great Leeder??????? moh, pls come clean on whether u took all these factors raised in the letter into account!!!!!! the pharma lecturer not only brought up the issue of statistical biasness like limpeh me did but also duration and effectiveness against possible mutation. https://pure.hud.ac.uk/en/persons/hamid-merchant pay zheng hu servants and ministers so much but still give crap policies. smelly peasants, song bo?????? https://www.bmj.com/content/371/bmj.m4471/rr-3 Rapid Response: Why Pfizer's or Moderna's CoViD-19 vaccine cannot be 95% effective? Dear Editor The phase III clinical trial results of the two frontrunner CoViD-19 vaccines developed by Pfizer [1] and Moderna [2] has claimed ~95% efficacy in their interim analysis. There are many reasons why such efficacy claims are premature and are likely to be proven incorrect in the long term. First, the Moderna’s claim is based on an interim analysis of vaccine efficacy from only 95 confirmed cases of 30,000 subjects in the trial; this is 0.32% of the total study subjects. If trial subjects are equally divided into vaccine and placebo groups, then the 90 and 5 confirmed CoViD-19 cases in the placebo and vaccine groups represents 0.6% and 0.03%, respectively. The prevalence of CoViD-19 confirmed positive cases in the USA [3] is currently estimated as ~4% of the total US population. Presuming the vaccine efficacy at 100% as the best-case scenario and if 4% of subjects in the placebo group were to contract the virus, at least 600 positive cases are expected in the trial. In contrast, the interim analysis was performed at only 95 confirmed cases, which is too early. The thresholds for the primary efficacy endpoints should have been set nearer to the geographical prevalence rates of CoViD-19. Currently, 99.4% of subjects in the placebo group have not contracted the virus either. This does not mean that the placebo is equally effective in preventing CoViD-19, it is just a matter of time. A similar issue is noted with Pfizer’s vaccine efficacy claims. Second, the trial subjects are living a new normal (social distancing, wearing masks, hand hygiene etc), which means that their chances of contracting the virus are already low (currently 4 in 100 in the USA). This would mean that we do not know if the subjects in the vaccine group were protected due to the vaccine or it is just because they have not had a contact yet. The definitive approach could involve deliberately challenging the trial subjects with the virus, like in preclinical trials, however, it is unlikely due to ethical and safety implications. In the absence of any definitive challenge test, it becomes imperative to not rush to conclude efficacy just within weeks of vaccination. Third, we do not know the antibody levels of the study subjects. What is the baseline antibodies titer in trial subjects against different coronaviruses? Have all subjects in the vaccine group produced antibodies and shown a cellular immune response? If yes, how the levels are like in comparison with the placebo group? Many in the placebo groups may have produced antibodies naturally should they had a viral contact before joining the trial. What is the antibody titer of the 95 subjects who are tested positive, particularly the five subjects who contracted the disease in the vaccine group? Have they all produced antibodies, how much, and what’s the T-cell response is like in them compared to other subjects? Fourth, whether the CoViD-19 test offered to all subjects in the trial before the interim assessment was made or restricted to symptomatic subjects only? If only selected subjects were offered the test, how the selection/judgement bias was mitigated? Moreover, it is likely to have a potential overlap of CoViD-19 symptoms with vaccine side effects hence another reason why all subjects should have been tested. Were trial subjects permitted to use OTC remedies for their post-vaccination symptoms and how this impacted on their probability of being offered a CoViD-19 test? What about the asymptomatic carriers – those who have had no symptoms but may still have contracted the virus? Fifth, how long the antibodies will live in vaccine subjects? The interim analysis was performed just two weeks after the subjects received a second dose of the vaccine which is certainly not enough time to decide on a global vaccination campaign. It is important to know if further booster doses may be required and whether the cellular immunity offers any future protection should the antibody titer falls. Sixth, the vaccine was tested against a placebo group that was only given a normal saline injection as a negative control. It would have been wise to include a BCG control group to enable a comparative assessment of CoViD-19 vaccine efficacy against the BCG vaccine which is already on immunisation schedule in many countries. BCG vaccine was hypothesised earlier in the pandemic [4] to be a potential predictor of the low CoViD-19 associated mortality seen in parts of the world. BCG has also shown some clinical efficacy against respiratory viruses and interestingly have also shown a protective effect in elderly subjects from some respiratory tract viral infections [5,6]. Seventh, since the vaccine is to be rolled out globally, the efficacy of vaccine may be established against a range of genetic variants of SARS-CoV-2 that are currently prevalent across the world. It may be interesting to spot the genetic variations where the vaccine did not respond. This will help in identifying potential demographics that are unlikely to benefit from a particular vaccine. In light of the above, the actual efficacy of the vaccine is likely to be much lower. This publicity, no doubt, has given the world great hope but can be disappointing to the public when the long-term efficacy was not as good as claimed in the interim assessment. Albeit not a surprise to many clinicians and scientists, the public may react badly. This may also fuel anti-vaccine thoughts and is not in the greater interest of public safety and may jeopardise their trust in science and medicine. Moreover, this is going to be the first mRNA-based vaccine being developed for the mass public use and a longer-term safety and efficacy assessment is inevitable. The mass publicity and celebration of the interim results, therefore, was a very bad idea and likely to have adverse implications.

the best part is that alrdy got many doctors and researchers with conscience in oct 2020 warn that the vaccine data r seriously questionable due to the clinical trial methodology liao. this bmj editor summarized the concerns of many of them, particularly pre-setting a low event rate, rather than using a higher or even time-limited experimental event rate of the sample. https://www.bmj.com/content/bmj/371/bmj.m4058.full.pdf most likely this pre-set low event rate resulted in type 2 error and thereby resulted in the high efficacies obtained by these vaccines. this pharm lecturer even better, not only raised questions abt the methodology of the clinical trials but also brought up questions such as duration and effectiveness against wuhan-19 mutation. on reading his letter on hindsight, unfortunately all his worries came true. https://www.bmj.com/content/371/bmj.m4471/rr-3 Rapid Response: Why Pfizer's or Moderna's CoViD-19 vaccine cannot be 95% effective? wahahahahhahha

the Great Leeder says wuhan-19 under control. so this wuhan-19 surge is the fault of u smelly vaxxed and unvaxxed peasants. not the fault of the Great Leeder or pappy, ok????? so the Great Leader commands u smelly peasants to go out and spend to stimulate the economy. the Great Leeder also wants the border to be fully reopened by end yr.

most likely will contract a reactivated los angeles class or trafalgar class under joint us-uk supervision b4 building a new one. too far advanced along the pipeline for alzheimer biden to cancel. the ozs will also feel safer since white house will have a corrupt president for the next 3yrs.

this is the least of winnie's worries. short sellers in hk r now shorting greenland. wahahahahaha

jin kumgong. gst is 7% while sgs 30y is 1.89% theoretical nim is 5.11% huat ah!!!!!!!

ur atb friend looking forward to u paying and leaving so that she can serve the next kgk. wahahahahaha

u see what happened in june at tan tock seng is alrdy warning liao. nb, use my pigu think also know if there is outbreak in hospital means there is serious issue with vaccine effectiveness liao. zheng hu jin kumgong. wahahahahahhahah

i dont want to end up walking like a guniang.

jin kumgong. the crux of the problem is the short duration of the vaccines' effectiveness. the human body is not going to magically produce longer-lasting immunity just becos of boaster shot.

jin kumgong. use my pigu think also know the vaccines sure will have alot of issues one. nb, i alrdy said last nov that efficacy most likely severely overestimated liao becos of flaws in the clinical trials and limitation of short-duration data. wahahahahahah

actually is whole world. wahahahahhahah

tiongland also has a manufacturing problem. their metallurgy technology is at least 3 generations behind us, russia and germany. thats why cannot build jet turbine blade, composite armor or high tensile grade a military steel. wahhahahahahhahaha

sure will have alot of those ymca type buy one.

how much murukku can sell now since its an impulse food???? maybe the mother shld sell kueh instead at the morning market, sure will have better business.

jin kumgong. i alrdy said that there is a need to tighten monetary policy since 2013 liao to prevent asset inflation and breakdown of transmission mechanism. now see what happen when u dont listen to Milton Friedman and keep on using Keynesian quantitative easing. wahahahahahahah

means time to look for bones to pick liao. wahahahahhahahhaha

alrdy said that construction industry needs to do more mechanization and automation since 2000 liao but zheng hu no listen. wahahahahahaha https://www.researchgate.net/publication/221786461_Trends_in_Robotics_and_Automation_in_Construction